Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Potter, H. Cordell, A. Barton, A. Daly, K. Hyrich, D. Mann, A. Morgan, A. Wilson, J. Isaacs (2010)
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFκB signalling pathwaysAnnals of the Rheumatic Diseases, 69
M. Hoshino, T. Yoshio, S. Onishi, S. Minota (2012)
Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritisModern Rheumatology, 22
H. Schellekens (2002)
Bioequivalence and the immunogenicity of biopharmaceuticalsNature Reviews Drug Discovery, 1
M. Weinblatt, E. Keystone, D. Furst, L. Moreland, M. Weisman, C. Birbara, L. Teoh, S. Fischkoff, E. Chartash (2003)
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.Arthritis and rheumatism, 48 1
Dore Rk, S. Mathews, J. Schechtman, W. Surbeck, D. Mandel, A. Patel, L. Zhou, P. Peloso (2007)
The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis.Clinical and experimental rheumatology, 25 1
K. Bendtzen (2011)
Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?Arthritis and rheumatism, 63 4
E. Keystone, M. Schiff, J. Kremer, S. Kafka, M. Lovy, T. Devries, D. Burge (2004)
Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.Arthritis and rheumatism, 50 2
van Schouwenburg, A. P., Link (2012)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization
A. Jamnitski, G. Bartelds, M. Nurmohamed, P. Schouwenburg, D. Schaardenburg, S. Stapel, B. Dijkmans, L. Aarden, G. Wolbink (2010)
The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanerceptAnnals of the Rheumatic Diseases, 70
Swaminathan Sethu, Karthik Govindappa, Mohammad Alhaidari, M. Pirmohamed, Kevin Park, J. Sathish (2012)
Immunogenicity to Biologics: Mechanisms, Prediction and ReductionArchivum Immunologiae et Therapiae Experimentalis, 60
E. Kneepkens, C. Krieckaert, D. Kleij, M. Nurmohamed, I. Horst-Bruinsma, T. Rispens, G. Wolbink (2013)
Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-upAnnals of the Rheumatic Diseases, 74
S. Mahil, Z. Arkir, G. Richards, C. Lewis, J. Barker, Catherine Smith (2013)
Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single‐centre, cohort studyBritish Journal of Dermatology, 169
K. Bendtzen, P. Geborek, M. Svenson, Lotta Larsson, M. Kapetanovic, T. Saxne (2006)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.Arthritis and rheumatism, 54 12
T. Radstake, M. Svenson, A. Eijsbouts, F. Hoogen, C. Enevold, P. Riel, K. Bendtzen (2008)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritisAnnals of the Rheumatic Diseases, 68
A. Jamnitski, C. Krieckaert, M. Nurmohamed, M. Hart, B. Dijkmans, L. Aarden, A. Voskuyl, G. Wolbink (2013)
Patients non-responding to etanercept obtain lower etanercept concentrations compared to responding patients
J. Maneiro, E. Salgado, J. Gómez-Reino (2013)
Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis.JAMA internal medicine, 173 15
J. Smolen, R. Landewé, F. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, D. Aletaha, M. Buch, L. Gossec, T. Huizinga, J. Bijlsma, G. Burmester, B. Combe, M. Cutolo, C. Gabay, J. Gómez-Reino, M. Kouloumas, T. Kvien, E. Martı́n-Mola, I. McInnes, K. Pavelka, P. Riel, Marieke Scholte, D. Scott, T. Sokka, G. Valesini, R. Vollenhoven, K. Winthrop, J. Wong, A. Zink, D. Heijde (2010)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnnals of the Rheumatic Diseases, 69
M. Pouw, C. Krieckaert, M. Nurmohamed, D. Kleij, L. Aarden, T. Rispens, G. Wolbink (2015)
Key findings towards optimising adalimumab treatment: the concentration-effect curve.Annals of the rheumatic diseases, 74 3
H. Tilg, A. Moschen (2006)
Adipocytokines: mediators linking adipose tissue, inflammation and immunityNature Reviews Immunology, 6
data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design Acquisition of data
J. Bluett, C. Morgan, L. Thurston, D. Plant, K. Hyrich, A. Morgan, A. Wilson, J. Isaacs, L. Cordingley, A. Barton (2014)
Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohortRheumatology (Oxford, England), 54
J. Paramarta, D. Baeten (2014)
Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationArthritis Research & Therapy, 16
M. Jani, A. Barton, R. Warren, C. Griffiths, H. Chinoy (2013)
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseasesRheumatology (Oxford, England), 53
G. Bartelds, C. Krieckaert, M. Nurmohamed, P. Schouwenburg, W. Lems, J. Twisk, B. Dijkmans, L. Aarden, G. Wolbink (2011)
Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.JAMA, 305 14
M. Hart, H. Vrieze, D. Wouters, G. Wolbink, J. Killestein, E. Groot, L. Aarden, T. Rispens (2011)
Differential effect of drug interference in immunogenicity assays.Journal of immunological methods, 372 1-2
F. Arnett, S. Edworthy, D. Bloch, D. McShane, J. Fries, N. Cooper, L. Healey, S. Kaplan, M. Liang, H. Luthra, T. Medsger, D. Mitchell, D. Neustadt, R. Pinals, J. Schaller, J. Sharp, R. Wilder, G. Hunder (1988)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis and rheumatism, 31 3
C. Krieckaert, A. Jamnitski, M. Nurmohamed, P. Kostense, M. Boers, G. Wolbink (2012)
Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.Arthritis and rheumatism, 64 12
De Vries, M. Horst-Bruinsma, I. Nurmohamed, M. Aarden, L. Stapel, S. Peters, M. Denderen, J. Dijkmans, B. Wolbink, M. Wolbink (2008)
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitisAnnals of the Rheumatic Diseases, 68
F. Arnett (1990)
Revised criteria for the classification of rheumatoid arthritis.Orthopedic nursing, 9 2
A. Finckh, J. Simard, C. Gabay, P. Guerne (2005)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritisAnnals of the Rheumatic Diseases, 65
C. Laken, A. Voskuyl, J. Roos, M. Walsum, E. Groot, G. Wolbink, B. Dijkmans, L. Aarden (2006)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritisAnnals of the Rheumatic Diseases, 66
J. Smolen, R. Landewé, F. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. Wit, D. Aletaha, N. Betteridge, J. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J. Hazes, M. Kouloumas, T. Kvien, X. Mariette, K. Pavelka, P. Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D. Scott, T. Sokka-Isler, J. Wong, D. Heijde (2013)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnnals of the Rheumatic Diseases, 73
M. Weinblatt, J. Kremer, A. Bankhurst, K. Bulpitt, R. Fleischmann, Robert Fox, C. Jackson, M. Lange, D. Burge (1999)
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.The New England journal of medicine, 340 4
Kilpatrick Sj, M. Wood (1978)
Analysis and interpretation of data.The Journal of family practice, 7 1
C. Krieckaert, M. Nurmohamed, G. Wolbink (2012)
Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnnals of the Rheumatic Diseases, 71
P. Schouwenburg, G. Bartelds, M. Hart, L. Aarden, G. Wolbink, D. Wouters (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients.Journal of immunological methods, 362 1-2
S. Garces, J. Demengeot, E. Benito-Garcia (2012)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysisAnnals of the Rheumatic Diseases, 72
M. Prevoo, M. Hof, H. Kuper, M. Leeuwen, L. Putte, P. Riel (1995)
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis and rheumatism, 38 1
R. Aalberse, S. Stapel, J. Schuurman, T. Rispens (2009)
Immunoglobulin G4: an odd antibodyClinical & Experimental Allergy, 39
A. Gestel, M. Prevoo, M. Hof, M. Rijswijk, L. Putte, P. Riel (1996)
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.Arthritis and rheumatism, 39 1
F. Vincent, E. Morand, Kim Murphy, F. Mackay, X. Mariette, C. Marcelli (2012)
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspectiveAnnals of the Rheumatic Diseases, 72
Lars Klareskog, Markus Gaubitz, V. Rodríguez-valverde, Michel Malaise, M. Dougados, J. Wajdula, Etanercept Investigators (2011)
Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis.Clinical and experimental rheumatology, 29 2
Arthritis & Rheumatology – Wiley
Published: May 1, 2015
You can share this free article with as many people as you like with the url below! We hope you enjoy this feature!
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.